Tennessee Bill Seeks to Remove Genetic Testing Cost Barriers
Event summary
- Tennessee legislators introduced SB 1626 (Senate) and HB 1775 (House) on January 27, 2026.
- The legislation aims to eliminate out-of-pocket costs for clinically appropriate germline genetic testing and related screenings.
- Germline testing identifies inherited mutations present from birth, affecting 5-10% of breast cancer cases.
- Approximately 83% of patients undergoing multigene panel testing experience changes in their medical management based on results.
- Susan G. Komen is publicly supporting the legislation.
The big picture
This legislation reflects a growing trend toward proactive, personalized cancer care driven by advances in genetic testing. Removing financial barriers could significantly expand access to these tests, potentially leading to earlier diagnoses and improved outcomes, but also creating cost pressures on the healthcare system. The move signals a shift towards preventative healthcare and a recognition of the role of genetics in cancer risk assessment.
What we're watching
- Legislative Passage
- The bill's success hinges on navigating the Tennessee legislature, and potential amendments could significantly alter the scope of coverage and impact on healthcare providers.
- Reimbursement Models
- How insurers and state Medicaid programs adapt to cover these tests will determine the long-term financial sustainability of the program and impact on lab revenues.
- Adoption Rate
- The pace at which physicians and patients adopt the expanded testing options will dictate the actual impact on early detection rates and cancer outcomes.
Related topics